GleamWall
中文EN

JAZZ Jazz Pharmaceuticals plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1232524 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.5%
TTM net income YoY155.9%
TTM EPS YoY154.9%
Revenue 3-yr CAGR7.5%
Net income 3-yr CAGR37.1%

Margins

Gross margin—
Operating margin9.0%
Net margin4.4%
FCF margin34.4%
EBITDA margin9.8%

Returns

ROE5.1%
ROA1.8%
ROIC (approx.)4.3%
Asset turnover0.40x

Leverage & solvency

Liabilities / assets65.1%
Debt / equity1.33x
Current ratio1.82x
Interest coverage—

Cash quality & payout

Operating cash flow / net income8.22x
Accruals ratio-12.7%
Payout ratio—
Capex / revenue1.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.27B$4.07B
R&D expense$782.74M$884.00M
SG&A expense$1.81B$1.39B
Operating income-$430.24M$716.63M
Pretax income-$627.86M$470.35M
Income tax-$272.44M-$91.43M
Net income-$356.15M$560.12M
EBITDA-$388.64M$749.43M
EPS (basic)-5.849.06
EPS (diluted)-5.848.65
Weighted avg. shares (diluted)60.98M66.01M
Balance sheet
Cash & equivalents$1.39B$2.41B
Receivables$830.70M$716.76M
Inventory$417.00M$480.44M
Current assets$4.17B$4.63B
PP&E, net$199.90M$173.41M
Goodwill$1.83B$1.72B
Intangibles$4.43B$4.76B
Total assets$11.66B$12.01B
Current liabilities$2.24B$1.04B
Short-term debt$1.03B$31.00M
Long-term debt$4.33B$6.08B
Total debt$5.36B$6.11B
Total liabilities$7.34B$7.92B
Shareholders' equity$4.32B$4.09B
Net debt$3.97B$3.70B
Shares outstanding61.44M60.63M
Cash flow statement
Operating cash flow$1.36B$1.40B
Capital expenditure$58.75M$38.07M
Free cash flow$1.30B$1.36B
Investing cash flow-$1.51B-$508.19M
Financing cash flow-$873.38M$20.52M
Depreciation & amortization$41.60M$32.80M
Stock-based compensation$291.13M$248.04M
Share buybacks$125.02M$311.43M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.